Cipla Ltd
Incorporation year : 1935
Headquarter : Mumbai, India
Chairman : Y. K. Hamied
Present Head (MD and CEO) : Umang Vohra
Chief Financial Officer : Kedar Upadhey
Company Introduction
Cipla Ltd. is a leading medicine manufacturer in India. The company has about 1,500 pharmaceutical products
in more than 60 therapeutic categories. Some are sold domestically, while the rest reach international markets
in more than 150 countries. It offers prescription drugs for all kinds of ailments -- arthritis, cancer, depression -
as well as over-the-counter drugs for colds, oral hygiene, and skin care. Cipla leads the domestic retail
pharmaceutical market. The company also makes bulk drugs, agrochemicals, and animal products. Cipla has
earned a worldwide recognition for adhering to the highest standards of quality and has received approvals
from Ministries of Health of various nations and major international regulatory agencies.
Company History
Cipla was founded as The Chemical, Industrial, and Pharmaceutical Laboratories by Khwaja Abdul Hamied in
1935. The name of the Company was changed to ‘Cipla Limited’ on 20 July 1984. In the year 1985, US FDA
approved the company’s bulk drug manufacturing facilities.
Philosophy
Cipla has developed good positive image by providing support to cancer patients by introducing drugs at low
cost.
Slogan: Caring for life.
Vision: To be the first global biotech company to provide high quality products at affordable prices that will
enable access for millions of patients world-wide by the year 2025
Mission: Cipla’s mission is to be a leading global healthcare company which uses technology and innovation to
meet every day needs of all the patients.
Portfolio of Company; Products and Services it offers
Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal
care products, including Escitalopram (anti-depressant), Lamivudine and Fluticasone propionate. It is the
world’s largest manufacturer of antiretroviral drugs. Cipla currently manufactures more than 200 generic and
complex Active Pharmaceutical Ingredients (APIs).
Business in News
♦ Meditab Specialities Private Limited, a wholly owned subsidiary of the Company acquired 75% stake in
Mabpharm Private Limited (‘Mabpharm’).
♦ Cipla Limited has acquired in Oct, 2019 novel and patented anti-infective product, Elores, from Venus
Remedies Limited (“VRL”) for the Indian market to further strengthen its presence in the branded
Indian critical care space and as a part of its agenda to contribute to the fight against Anti-Microbial
Resistance (AMR).
https://www.cipla.com/press-releases-statements/cipla-acquires-novel-anti-infective-elores-further-anti-
microbial
♦ The 82-year-old chairman of pharmaceutical major Cipla (Prominent scientist and businessman Yusuf
Hamied ) has been made an Honorary Fellow of the prestigious body, comprising of many of the
world's most eminent scientists in the 2019 list of new fellows of the UK's Royal Society.
https://www.business-standard.com/article/pti-stories/cipla-chairman-hamied-receives-uk-royal-society-
honour-119041800962_1.html
For more information you may visit company website: www.cipla.com